甲状腺结节不典型细针抽吸细胞学检查中 ThyroSeq v3 基因组分类器的临床验证。
Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology.
机构信息
Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania.
出版信息
Cancer Cytopathol. 2019 Apr;127(4):225-230. doi: 10.1002/cncy.22112. Epub 2019 Feb 27.
Abstract
Molecular testing of thyroid fine‐needle aspiration specimens has been developed with the primary goals of resolving the uncertainty of indeterminate cytology and avoiding the diagnostic surgeries generally recommended for these patients. A recent prospective, double‐blinded, multicenter study reported the results of the clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate fine‐needle aspiration cytology.
摘要
甲状腺细针抽吸标本的分子检测已经发展起来，其主要目标是解决不确定的细胞学的不确定性，并避免对这些患者通常推荐的诊断性手术。最近一项前瞻性、双盲、多中心研究报告了 ThyroSeq v3 基因组分类器在具有不确定细针抽吸细胞学的甲状腺结节中的临床验证结果。
相似文献
1
Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology.甲状腺结节不典型细针抽吸细胞学检查中 ThyroSeq v3 基因组分类器的临床验证。
Cancer Cytopathol. 2019 Apr;127(4):225-230. doi: 10.1002/cncy.22112. Epub 2019 Feb 27.
2
Thyroid cytology smear slides: An untapped resource for ThyroSeq testing.甲状腺细胞学涂片：ThyroSeq 检测的未开发资源。
Cancer Cytopathol. 2021 Jan;129(1):33-42. doi: 10.1002/cncy.22331. Epub 2020 Jul 22.
3
Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.甲状腺结节中 ThyroSeq v3 基因组分类器用于癌症诊断的分析性能。
Cancer. 2018 Apr 15;124(8):1682-1690. doi: 10.1002/cncr.31245. Epub 2018 Jan 18.
4
Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.多基因基因组分类器在具有不确定细胞学的甲状腺结节中的表现：一项前瞻性盲法多中心研究。
JAMA Oncol. 2019 Feb 1;5(2):204-212. doi: 10.1001/jamaoncol.2018.4616.
5
The role of ThyroSeq V3 testing in the management of patients with indeterminate thyroid nodules on fine needle aspiration.ThyroSeq V3 检测在细针穿刺不确定甲状腺结节患者管理中的作用。
Diagn Cytopathol. 2021 Jul;49(7):838-841. doi: 10.1002/dc.24751. Epub 2021 Apr 17.
6
Benign call rate and molecular test result distribution of ThyroSeq v3.良性肿瘤的检出率和 ThyroSeq v3 的分子检测结果分布。
Cancer Cytopathol. 2019 Mar;127(3):161-168. doi: 10.1002/cncy.22088. Epub 2018 Dec 18.
7
Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis.167 基因表达分类器（GEC）和 ThyroSeq v2 在术前评估甲状腺结节中的诊断准确性评估：双变量/HROC 荟萃分析。
Endocr Pathol. 2019 Mar;30(1):8-15. doi: 10.1007/s12022-018-9560-5.
8
9
The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Health Care Setting.在加拿大公共医疗保健环境中，甲状腺结节手术管理中 ThyroSeq v3 分子检测的作用。
Thyroid. 2020 Sep;30(9):1280-1287. doi: 10.1089/thy.2019.0539. Epub 2020 May 5.
10
Role of Ancillary Techniques in Thyroid Cytology Specimens.辅助技术在甲状腺细胞学标本中的作用
Acta Cytol. 2020;64(1-2):40-51. doi: 10.1159/000496502. Epub 2019 Apr 4.
引用本文的文献
1
High Allele Frequency Signals Increased Risk of Promoter Mutations in Thyroid Tumors.高等位基因频率信号增加甲状腺肿瘤中启动子突变的风险。
Cancers (Basel). 2025 Aug 30;17(17):2851. doi: 10.3390/cancers17172851.
2
Role of Publicly-Funded Molecular Testing in Surgical Management of Thyroid Nodules within Canadian Medicare: Clinical Assessment of ThyroSeqv3 Molecular Test Pilot Project at McGill University.加拿大医疗保险制度下公共资助的分子检测在甲状腺结节外科治疗中的作用：麦吉尔大学ThyroSeqv3分子检测试点项目的临床评估
J Otolaryngol Head Neck Surg. 2025 Jan-Dec;54:19160216251336687. doi: 10.1177/19160216251336687. Epub 2025 May 28.
3
Description of a New miRNA Signature for the Surgical Management of Thyroid Nodules.一种用于甲状腺结节手术管理的新miRNA标志物描述
Cancers (Basel). 2024 Dec 18;16(24):4214. doi: 10.3390/cancers16244214.
4
Performance of the AmpliSeq NGS panel in thyroid nodules with indeterminate cytology.AmpliSeq二代测序检测板在甲状腺结节细针穿刺结果不确定中的应用
Eur Thyroid J. 2025 Jan 21;14(1). doi: 10.1530/ETJ-24-0160. Print 2025 Feb 1.
5
Molecular Markers in Follicular and Oncocytic Thyroid Carcinomas: Clinical Application of Molecular Genetic Testing.滤泡性和嗜酸细胞性甲状腺癌的分子标志物：分子遗传学检测的临床应用。
Curr Oncol. 2024 Oct 1;31(10):5919-5928. doi: 10.3390/curroncol31100441.
6
Small Multi-Gene DNA Panel Can Aid in Reducing the Surgical Resection Rate and Predicting the Malignancy Risk of Thyroid Nodules.多基因小 DNA 面板有助于降低甲状腺结节的手术切除率并预测其恶性风险。
Endocrinol Metab (Seoul). 2024 Oct;39(5):777-792. doi: 10.3803/EnM.2024.2034. Epub 2024 Oct 14.
7
Editorial: Molecular characterization of thyroid lesions in the era of "next generation" techniques: volume II.社论：“下一代”技术时代甲状腺病变的分子特征：第二卷
Front Endocrinol (Lausanne). 2024 Jul 29;15:1460239. doi: 10.3389/fendo.2024.1460239. eCollection 2024.
8
: A Novel Receptor Tyrosine Kinase Fusion Oncogene in Pediatric Thyroid Cancer.小儿甲状腺癌中的一种新型受体酪氨酸激酶融合癌基因。
Thyroid. 2024 Oct;34(10):1308-1313. doi: 10.1089/thy.2024.0224. Epub 2024 Aug 27.
9
Does the likelihood of malignancy in thyroid nodules with RAS mutations increase in direct proportion with the allele frequency percentage?甲状腺结节 RAS 突变的恶性可能性是否与等位基因频率百分比成正比增加？
J Otolaryngol Head Neck Surg. 2023 Feb 11;52(1):12. doi: 10.1186/s40463-022-00611-8.
10
Coexisting Molecular Alterations Increase the Risk of Malignancy in Thyroid Nodules with Copy Number Alterations.共存的分子改变增加了具有拷贝数改变的甲状腺结节发生恶性肿瘤的风险。
Cancers (Basel). 2022 Dec 13;14(24):6149. doi: 10.3390/cancers14246149.
本文引用的文献
1
Benign call rate and molecular test result distribution of ThyroSeq v3.良性肿瘤的检出率和 ThyroSeq v3 的分子检测结果分布。
Cancer Cytopathol. 2019 Mar;127(3):161-168. doi: 10.1002/cncy.22088. Epub 2018 Dec 18.
2
Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.多基因基因组分类器在具有不确定细胞学的甲状腺结节中的表现：一项前瞻性盲法多中心研究。
JAMA Oncol. 2019 Feb 1;5(2):204-212. doi: 10.1001/jamaoncol.2018.4616.
3
Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes.Hürthle 细胞癌的综合基因组分析揭示了致癌驱动因素、反复发生的线粒体突变和独特的染色体景观。
Cancer Cell. 2018 Aug 13;34(2):256-270.e5. doi: 10.1016/j.ccell.2018.07.002.
4
Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma.广泛的染色体缺失和线粒体 DNA 改变作为 Hurthle 细胞癌的遗传驱动因素。
Cancer Cell. 2018 Aug 13;34(2):242-255.e5. doi: 10.1016/j.ccell.2018.06.013.
5
Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules.基因组测序分类器在术前诊断细胞学不确定的甲状腺结节中的性能。
JAMA Surg. 2018 Sep 1;153(9):817-824. doi: 10.1001/jamasurg.2018.1153.
6
The Diagnosis and Management of Thyroid Nodules: A Review.甲状腺结节的诊断与处理：综述
JAMA. 2018 Mar 6;319(9):914-924. doi: 10.1001/jama.2018.0898.
7
Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.甲状腺结节中 ThyroSeq v3 基因组分类器用于癌症诊断的分析性能。
Cancer. 2018 Apr 15;124(8):1682-1690. doi: 10.1002/cncr.31245. Epub 2018 Jan 18.
8
Distinguishing parathyroid and thyroid lesions on ultrasound-guided fine-needle aspiration: A correlation of clinical data, ancillary studies, and molecular analysis.超声引导下细针穿刺鉴别甲状旁腺和甲状腺病变：临床数据、辅助检查及分子分析的相关性
Cancer Cytopathol. 2017 Sep;125(9):674-682. doi: 10.1002/cncy.21888. Epub 2017 Jun 16.
9
American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.美国甲状腺协会甲状腺结节和分化型甲状腺癌管理指南工作组关于将无侵袭性的包膜性滤泡变异型乳头状甲状腺癌重新命名为具有乳头状核特征的非侵袭性滤泡性甲状腺肿瘤的审查与建议。
Thyroid. 2017 Apr;27(4):481-483. doi: 10.1089/thy.2016.0628. Epub 2017 Feb 21.
10
Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): A changing paradigm in thyroid surgical pathology and implications for thyroid cytopathology.具有乳头样核特征的非侵袭性滤泡性甲状腺肿瘤（NIFTP）：甲状腺外科病理学的转变范例及其对甲状腺细胞病理学的影响
Cancer Cytopathol. 2016 Sep;124(9):616-20. doi: 10.1002/cncy.21744. Epub 2016 May 20.
Zotero 插件